Mark Hammond joins PBD Biotech
Novel diagnostic developer PBD Biotech announces the appointment of new CEO Mark Hammond to drive the company's expansion.
Mark has held a number of senior leadership roles throughout his 20 years’ experience in public and private healthcare. His appointment is announced as PBD Biotech declares its first multi-million pound funding round to support the test’s regulatory validation and ongoing commercialisation.
Commenting on his new role, Mark said, I am excited about what the future holds for PBD Biotech, and keen to build on our fast-growing reputation as a leader in mycobacterial diagnostics.
Mark succeeds Dr Berwyn Clarke, who co-founded the company and, following his retirement as CEO, is to become a non-executive director on PBD Biotech’s Board.
